JMP Securities Starts Aquestive Therapeutics (AQST) at Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
RBC Capital Starts Aquestive Therapeutics (AQST) at Outperform
August 20, 2018 8:07 AM EDTRBC Capital analyst Randall Stanicky initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with an Outperform rating and a price target of $23.00.
Stanicky said with stable cash flows from Suboxone behind it and a broad pipeline ahead of it, AQST is well... More
BMO Capital Starts Aquestive Therapeutics (AQST) at Outperform
August 20, 2018 5:15 AM EDTBMO Capital analyst Gary Nachman initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Outperform rating and a price target of $26.00.
The analyst comments "AQST has best in-class PharmFilm drug delivery technology and a proven track record developing a robust portfolio of... More
